Breast cancer stem cells: Current advances and clinical implications

Methods in Molecular Biology

Volumn 1293, Issue , 2015, Pages 1-49

  Luo, Ming ^a   Clouthier, Shawn G ^a   Deol, Yadwinder ^a   Liu, Suling ^a   Nagrath, Sunitha ^a   Azizi, Ebrahim ^a   Wicha, Max S ^a  

^a NONE

Author keywords

Breast cancer; Cancer stem cells (CSCs); Circulating tumor cells (CTCs); Patient derived xenograft (PDX); Phenotypic plasticity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; WNT PROTEIN; BIOLOGICAL MARKER;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM CELL; BREAST METASTASIS; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL ISOLATION; CELL RENEWAL; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VITRO STUDY; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; BREAST NEOPLASMS; CELL SELF-RENEWAL; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; PHENOTYPE; TUMOR EMBOLISM;

ANIMALS; BIOMARKERS; BREAST NEOPLASMS; CELL SELF RENEWAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84930664656     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2519-3_1     Document Type: Article

References (282)

1. Sternlicht MD et al (2006) Hormonal and local control of mammary branching morphogenesis. Differentiation 74(7):365–381
2. Hinck L, Silberstein GB (2005) Key stages in mammary gland development: the mammary end bud as a motile organ. Breast Cancer Res 7(6):245–251
3. Hennighausen L, Robinson GW (2005) Information networks in the mammary gland. Nat Rev Mol Cell Biol 6(9):715–725
4. Smalley M, Ashworth A (2003) Stem cells and breast cancer: a field in transit. Nat Rev Cancer 3(11):832–844
5. Kordon EC, Smith GH (1998) An entire functional mammary gland may comprise the progeny from a single cell. Development 125(10):1921–1930
6. Smith GH (1996) Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res Treat 39(1):21–31
7. Asselin-Labat ML et al (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9(2):201–209
8. Stingl J et al (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439(7079):993–997
9. Shackleton M et al (2006) Generation of a functional mammary gland from a single stem cell. Nature 439(7072):84–88
10. Sleeman KE et al (2006) CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res 8(1):R7
11. Shipitsin M et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259–273
12. Villadsen R et al (2007) Evidence for a stem cell hierarchy in the adult human breast. J Cell Biol 177(1):87–101
13. Lim E et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907–913
14. Eirew P et al (2008) A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 14(12):1384–1389
15. Keller PJ et al (2011) Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 109:2772–2777
16. Visvader JE (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 23(22):2563–2577
17. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730–737
18. Wicha MS, Liu S, Dontu G (2006) Cancer stem cells: an old idea—a paradigm shift. Cancer Res 66(4):1883–1890, discussion 1895-6
19. Liu S, Wicha MS (2010) Targeting breast cancer stem cells. J Clin Oncol 28(25):4006–4012
20. Charafe-Jauffret E et al (2008) Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75(2):75–84
21. Al-Hajj M et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100(7):3983–3988
22. Ginestier C et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567
23. Liu S et al (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2(1):78–91
24. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401
25. Collins AT et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946–10951
26. Patrawala L et al (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12):1696–1708
27. O’Brien CA et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106–110
28. Ricci-Vitiani L et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111–115
29. Li C et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030–1037
30. Ma S et al (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132(7):2542–2556
31. Ma S et al (2010) MiR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7(6):694–707
32. Kim CF et al (2005) Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121(6):823–835
33. Prince ME et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104(3):973–978
34. Mukherjee S (2010) The emperor of all maladies: a biography of cancer. 1st Scribner hardcover ed, vol 14. Scribner, New York, NY, p 571, 8 p. of plates
35. Huntly BJ, Gilliland DG (2005) Cancer biology: summing up cancer stem cells. Nature 435(7046):1169–1170
36. Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51(1):1–28
37. Xu Q et al (2009) Isolation of tumour stem-like cells from benign tumours. Br J Cancer 101(2):303–311
38. Clay MR et al (2010) Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32(9):1195–1201
39. Silva IA et al (2011) Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71(11):3991–4001
40. Krishnamurthy S et al (2010) Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 70(23):9969–9978
41. Fang D et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65(20):9328–9337
42. Quintana E et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456(7222):593–598
43. Roesch A et al (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141(4):583–594
44. Boiko AD et al (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466(7302):133–137
45. Luo Y et al (2012) ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells 30(10):2100–2113
46. Kelly PN et al (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317(5836):337
47. Charafe-Jauffret E et al (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4):1302–1313
48. Charafe-Jauffret E et al (2013) ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res 73(24):7290–7300
49. Pece S et al (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62–73
50. Bunting KD (2002) ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20(1):11–20
51. Hadnagy A et al (2006) SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312(19):3701–3710
52. Hirschmann-Jax C et al (2004) A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 101(39):14228–14233
53. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 101(3):781–786
54. Clarke RB et al (2005) A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol 277(2):443–456
55. Alvi AJ et al (2003) Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 5(1):R1–R8
56. Clayton H, Titley I, Vivanco M (2004) Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res 297(2):444–460
57. Welm BE et al (2002) Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 245(1):42–56
58. Patrawala L et al (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65(14):6207–6219
59. Britton KM et al (2012) Breast cancer, side population cells and ABCG2 expression. Cancer Lett 323(1):97–105
60. Nakanishi T et al (2010) Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 102(5):815–826
61. Mani SA et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
62. Marotta LL et al (2011) The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 121(7):2723–2735
63. Honeth G et al (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3):R53
64. Meyer MJ et al (2010) CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 70(11):4624–4633
65. Friedrichs K et al (1995) High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Res 55(4):901–906
66. Lipscomb EA et al (2005) The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res 65(23):10970–10976
67. Chute JP et al (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 103(31):11707–11712
68. Storms RW et al (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 96(16):9118–9123
69. Ludeman SM (1999) The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 5(8):627–643
70. Cheung AM et al (2007) Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21(7):1423–1430
71. Sullivan JP et al (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70(23):9937–9948
72. Huang EH et al (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69(8):3382–3389
73. Carpentino JE et al (2009) Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 69(20):8208–8215
74. van den Hoogen C et al (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70(12):5163–5173
75. Dontu G et al (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17(10):1253–1270
76. D’Angelo RC, Wicha MS (2010) Stem cells in normal development and cancer. Prog Mol Biol Transl Sci 95:113–158
77. Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69(24):9245–9253
78. Hendrikx PJ et al (1996) Homing of fluorescently labeled murine hematopoietic stem cells. Exp Hematol 24(2):129–140
79. Lanzkron SM, Collector MI, Sharkis SJ (1999) Homing of long-term and short-term engrafting cells in vivo. Ann N Y Acad Sci 872:48–54, discussion 54-6
80. Askenasy N, Farkas DL (2002) Optical imaging of PKH-labeled hematopoietic cells in recipient bone marrow in vivo. Stem Cells 20(6):501–513
81. Cicalese A et al (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138(6):1083–1095
82. Lassailly F, Griessinger E, Bonnet D (2010) “Microenvironmental contaminations” induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. Blood 115(26):5347–5354
83. Liu S, Clouthier SG, Wicha MS (2012) Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia 17(1):15–21
84. Liu S et al (2012) MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet 8(6):e1002751
85. Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15(6):740–746
86. Yang J et al (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927–939
87. Wu Y et al (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15(5):416–428
88. Yang MH et al (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10(3):295–305
89. Samavarchi-Tehrani P et al (2010) Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 7(1):64–77
90. Brabletz T (2012) To differentiate or not: routes towards metastasis. Nat Rev Cancer 12(6):425–436
91. Tsai JH et al (2012) Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22(6):725–736
92. Ocana OH et al (2012) Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22(6):709–724
93. Malanchi I et al (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481(7379):85–89
94. Korpal M et al (2011) Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17(9):1101–1108
95. Stankic M et al (2013) TGF-beta-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 5(5):1228–1242
96. Herschkowitz JI et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76
97. Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
98. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869–10874
99. Sotiriou C et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100(18):10393–10398
100. Chang JC et al (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23(6):1169–1177
101. Creighton CJ et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106(33):13820–13825
102. Molyneux G et al (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7(3):403–417
103. Proia TA et al (2011) Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8(2):149–163
104. Keller PJ et al (2012) Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 109(8):2772–2777
105. Van Keymeulen A et al (2011) Distinct stem cells contribute to mammary gland development and maintenance. Nature 479(7372):189–193
106. Jeselsohn R et al (2010) Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 17(1):65–76
107. Liu S et al (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 105(5):1680–1685
108. Lagadec C et al (2010) Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 12(1):R13
109. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24):1777–1785
110. Karimi-Busheri F et al (2010) Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 12(3):R31
111. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10(2):R25
112. Shafee N et al (2008) Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68(9):3243–3250
113. Woodward WA et al (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104(2):618–623
114. Diehn M et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458(7239):780–783
115. Yu F et al (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6):1109–23
116. Zielske SP et al (2011) Ablation of breast cancer stem cells with radiation. Transl Oncol 4(4):227–233
117. Li X et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100(9):672–679
118. Korkaya H et al (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27(47):6120–6130
119. Tanei T et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234–4241
120. Behbod F et al (2006) Transcriptional profiling of mammary gland side population cells. Stem Cells 24(4):1065–1074
121. Ithimakin S et al (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73(5):1635–1646
122. Sladek NE (2003) Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17(1):7–23
123. Su Y et al (2010) Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 19(2):327–337
124. Kim MP et al (2011) ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6(6):e20636
125. Landen CN Jr et al (2010) Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186–3199
126. Magni M et al (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87(3):1097–1103
127. Moreb J et al (1996) Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 3(1):24–30
128. Moreb JS et al (2000) Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 293(2):390–396
129. Sun QL et al (2011) Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin Oncol 137(3):521–532
130. Sladek NE et al (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49(4):309–321
131. Croker AK, Allan AL (2012) Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res Treat 133(1):75–87
132. Ward JF (1985) Biochemistry of DNA lesions. Radiat Res Suppl 8:S103–S111
133. Powell S, McMillan TJ (1990) DNA damage and repair following treatment with ionizing radiation. Radiother Oncol 19(2):95–108
134. Kryston TB et al (2011) Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res 711(1–2):193–201
135. Ito K et al (2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431(7011):997–1002
136. Ito K et al (2006) Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 12(4):446–451
137. Tothova Z et al (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128(2):325–339
138. Miyamoto K et al (2007) Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1(1):101–112
139. Guzman ML et al (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11):4163–4169
140. Bao S et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760
141. Yin H, Glass J (2011) The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 6(9):e24080
142. Zhang M, Atkinson RL, Rosen JM (2010) Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A 107(8):3522–3527
143. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45
144. Cheng C, Yaffe MB, Sharp PA (2006) A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20(13):1715–1720
145. Orian-Rousseau V et al (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16(23):3074–3086
146. Sherman LS et al (2000) CD44 enhances neuregulin signaling by Schwann cells. J Cell Biol 150(5):1071–1084
147. Bourguignon LY et al (1997) Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem 272(44):27913–27918
148. Draffin JE et al (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64(16):5702–5711
149. Hiraga T, Ito S, Nakamura H (2013) Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 73(13):4112–4122
150. Brown RL et al (2011) CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 121(3):1064–1074
151. Kouros-Mehr H et al (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141–152
152. Schabath H et al (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119(Pt 2):314–325
153. Cojoc M et al (2013) Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther 6:1347–1361
154. Sheridan C et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59
155. Liu R et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356(3):217–226
156. Balic M et al (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12(19):5615–5621
157. Liu H et al (2010) Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci U S A 107(42):18115–18120
158. Theodoropoulos PA et al (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288(1):99–106
159. Charafe-Jauffret E et al (2010) Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16(1):45–55
160. Liu S et al (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71(2):614–624
161. Lianidou ES, Markou A (2011) Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57(9):1242–1255
162. Murray NP et al (2012) Redefining micrometastasis in prostate cancer: a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis—implications in determining local or systemic treatment for biochemical failure after radical prostatectomy. Int J Mol Med 30(4):896–904
163. Cristofanilli M et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420–1430
164. Joosse SA, Pantel K (2013) Biologic challenges in the detection of circulating tumor cells. Cancer Res 73(1):8–11
165. Maheswaran S et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366–377
166. Nagrath S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239
167. Baccelli I et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544
168. Zhang L et al (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5(180): 180ra48
169. Yu M et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584
170. Pestrin M et al (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134(1):283–289
171. Giordano A et al (2011) Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat 129(2):451–458
172. Cohen SJ et al (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20(7):1223–1229
173. Olmos D et al (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 20(1):27–33
174. Allard WJ et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904
175. Whitesides GM (2006) The origins and the future of microfluidics. Nature 442(7101):368–373
176. Khandurina J et al (2000) Integrated system for rapid PCR-based DNA analysis in microfluidic devices. Anal Chem 72(13):2995–3000
177. Erickson D et al (2004) Electrokinetically controlled DNA hybridization microfluidic chip enabling rapid target analysis. Anal Chem 76(24):7269–7277
178. Haeberle S, Zengerle R (2007) Microfluidic platforms for lab-on-a-chip applications. Lab Chip 7(9):1094–1110
179. Gleghorn JP et al (2010) Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 10(1):27–29
180. Adams AA et al (2008) Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc 130(27):8633–8641
181. Stott SL et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397
182. Yoon HJ et al (2013) Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 8(10):735–741
183. Lin HK et al (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16(20):5011–5018
184. Vona G et al (2004) Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3):792–797
185. Zheng S et al (2007) Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 1162(2):154–161
186. Zheng S et al (2011) 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13(1):203–213
187. Kuo JS et al (2010) Deformability considerations in filtration of biological cells. Lab Chip 10(7):837–842
188. Zhou J, Papautsky I (2013) Fundamentals of inertial focusing in microchannels. Lab Chip 13(6):1121–1132
189. Bhagat AA, Kuntaegowdanahalli SS, Papautsky I (2008) Continuous particle separation in spiral microchannels using Dean flows and differential migration. Lab Chip 8(11):1906–1914
190. Hou HW et al (2013) Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 3:1259
191. Ozkumur E et al (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5(179):179ra47
192. Zhang W et al (2012) Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proc Natl Acad Sci U S A 109(46):18707–18712
193. Kuperwasser C et al (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 101(14):4966–4971
194. DeRose YS et al (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514–1520
195. Zhang X et al (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73(15):4885–4897
196. Marangoni E et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998
197. Beckhove P et al (2003) Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer 105(4):444–453
198. Bergamaschi A et al (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3(5–6):469–482
199. du Manoir S et al (2013) Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. Mol Oncol 8:431–43
200. Clarke R et al (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53(1):25–71
201. Cottu P et al (2012) Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 133(2):595–606
202. Kabos P et al (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432
203. Ginestier C et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485–497
204. Turkson J, Jove R (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19(56):6613–6626
205. Redell MS, Tweardy DJ (2005) Targeting transcription factors for cancer therapy. Curr Pharm Des 11(22):2873–2887
206. Chen Z, Han ZC (2008) STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28(2):185–200
207. Dave B et al (2012) Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One 7(8):e30207
208. Noguera-Troise I et al (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122):1032–1037
209. Ridgway J et al (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444(7122):1083–1087
210. Scehnet JS et al (2007) Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109(11):4753–4760
211. Hoey T et al (2009) DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5(2):168–177
212. Schott AF et al (2013) Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19(6):1512–1524
213. Todaro M et al (2013) Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 73(21):6393–6400
214. Ingham PW, McMahon AP (2001) Hedgehog signaling in animal development: paradigms and principles. Genes Dev 15(23):3059–3087
215. Liu S et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66(12):6063–6071
216. Kubo M et al (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64(17):6071–6074
217. Tremblay MR et al (2008) Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists. J Med Chem 51(21):6646–6649
218. Robarge KD et al (2009) GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 19(19):5576–5581
219. Olive KP et al (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457–1461
220. Chiba S (2006) Notch signaling in stem cell systems. Stem Cells 24(11):2437–2447
221. Roy M, Pear WS, Aster JC (2007) The multifaceted role of Notch in cancer. Curr Opin Genet Dev 17(1):52–59
222. Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3(10):756–767
223. Jhappan C et al (1992) Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 6(3):345–355
224. Bouras T et al (2008) Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3(4):429–441
225. Reedijk M et al (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65(18):8530–8537
226. Harrison H et al (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70(2):709–718
227. Zang S et al (2010) RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol Rep 23(4):893–899
228. Olsauskas-Kuprys R, Zlobin A, Osipo C (2013) Gamma secretase inhibitors of Notch signaling. Onco Targets Ther 6:943–955
229. Lindsay J et al (2008) ErbB2 induces Notch1 activity and function in breast cancer cells. Clin Transl Sci 1(2):107–115
230. Farnie G et al (2013) Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. PLoS One 8(2):e56840
231. Osipo C et al (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27(37):5019–5032
232. Won HY et al (2012) Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway. FASEB J 26(12):5002–5013
233. Rexer BN, Arteaga CL (2013) Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Res 73(13):3817–3820
234. Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127
235. Korkaya H et al (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7(6):e1000121
236. Junttila TT et al (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5):429–440
237. Serra V et al (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022–8030
238. Andre F et al (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110–5115
239. Chakrabarty A et al (2013) Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 73(3):1190–1200
240. Klaus A, Birchmeier W (2008) Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8(5):387–398
241. Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810
242. Badders NM et al (2009) The Wnt receptor, Lrp5, is expressed by mouse mammary stem cells and is required to maintain the basal lineage. PLoS One 4(8):e6594
243. Bafico A et al (2004) An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6(5):497–506
244. Klopocki E et al (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 25(3):641–649
245. Nagahata T et al (2003) Amplification, up-regulation and over-expression of DVL-1, the human counterpart of the Drosophila disheveled gene, in primary breast cancers. Cancer Sci 94(6):515–518
246. Nakopoulou L et al (2006) Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome. Mod Pathol 19(4):556–563
247. Piva et al (2014) Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 6:66–79
248. Li Y et al (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 100(26):15853–15858
249. Liu BY et al (2004) The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci U S A 101(12):4158–4163
250. Conley SJ et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109(8):2784–2789
251. Yang ZQ et al (2009) Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers. Int J Cancer 125(7):1613–1621
252. He B et al (2004) A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6(1):7–14
253. DeAlmeida VI et al (2007) The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 67(11):5371–5379
254. Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7(2):139–147
255. Karnoub AE et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557–563
256. Asselin-Labat ML et al (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299):798–802
257. Fillmore CM et al (2010) Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A 107(50):21737–21742
258. Pierce BL et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27(21):3437–3444
259. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
260. Sansone P et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12):3988–4002
261. Conze D et al (2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61(24):8851–8858
262. Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139(4):693–706
263. Korkaya H et al (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47(4):570–584
264. Germain D, Frank DA (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13(19):5665–5669
265. Lin L et al (2013) Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24− subpopulations of breast cancer cells. PLoS One 8(12):e82821
266. Yu F et al (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29(29):4194–4204
267. Shimono Y et al (2009) Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138(3):592–603
268. World Health Organization (2012) Cancer Fact Sheet N297. http://publications.cancerresearchuk.org/downloads/product/CS_REPORT_WORLD.pdf
269. Phend C (2011) Breast cervical cancer kill 625,000 women each year. (3/25/12). http://abcnews.go.com/Health/breast-cervical-cancers-rise-globally/story?id=14529241
270. National Cancer Institute. Surveillance epidemiology and end results: SEER stat fact sheets. Accessed 31 Mar 12. http://seer.cancer.gov/
271. American Cancer Society. Cancer facts and figures 2012. Accessed 31 Mar 12. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/
272. Perez EA et al (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28(28):4307–4315
273. Recht A et al (1996) The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 334(21):1356–1361
274. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792
275. Hedge SR, Sun W, Lynch JP (2008) Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2(1):135–149
276. Silvestri GA, Rivera MP (2005) Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 128(6):3975–3984
277. Sherbenou DW, Druker BJ (2007) Applying the discovery of the Philadelphia chromosome. J Clin Invest 117(8):2067–2074
278. Sakariassen PO, Immervoll H, Chekenya M (2007) Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 9(11):882–892
279. Brekelmans CT et al (2007) Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43(5):867–876
280. Korkaya H, Wicha MS (2007) Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 21(5):299–310
281. Houston S (2011) Stemming the tide. ChemistryWorld.org. http://www.rsc.org/chemistryworld/restricted/2011/September/StemmingTheTide.asp
282. Markey K (2009) Firms seek to prove cancer stem cell hypothesis. Bio Market Trends. 29(18). http://www.genengnews.com/gen-articles/firms-seek-to-prove-cancer-stem-cell-hypothesis/3066/